Therapy Name | JNJ-61610588 |
Therapy Description |
JNJ-61610588 is an immune checkpoint inhibitor and monoclonal antibody that targets the T-cell receptor, VISTA (PD1H), V-type immunoglobulin domain-containing suppressor of T-cell activation, to evoke an anti-tumor response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-61610588 | JNJ 61610588 | Immune Checkpoint Inhibitor 99 | JNJ-61610588 is an immune checkpoint inhibitor and monoclonal antibody that targets the T-cell receptor, VISTA (PD1H), V-type immunoglobulin domain-containing suppressor of T-cell activation, to evoke an anti-tumor response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02671955 | Phase I | JNJ-61610588 | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated |